Mizuho analyst Mara Goldstein downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Neutral and lowers the price target from $16 to $4.
LogicMark, Inc. Announces Strong Revenue And Margin Growth For The Year Ended 2022; Cash Balance On December 31, 2022 Was $7M; FY22 Revenue $11.9M
Full Year 2022 Financial Results
Revenue for the year ended December 31, 2022, was $11.9 million, up 19% from the prior year. The increase in revenues resulted from improved sales to VA
